SIGACHI37.60

Sigachi Industries Limited

· Pharma & Health
₹ CrorePeersLINCOLNTHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYNGLFINEMcap ₹1,437 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)161.03146.22134.51134.51
Receivable Days (DSO)137.27137.31171.26171.26
Payable Days (DPO)109.0655.30107.49111.32
Cash Conversion Cycle (days)189.24228.23198.28194.45
Working Capital Turnover3.182.334.023.96
Asset Turnover0.570.580.570.57
Cash Conversion (CFO/Net Income)0.230.38-0.05-0.05
CFO/EBITDA0.170.270.080.08
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.